8.6 USD
-0.45 (-4.97%)
8.78 USD
+0.18 (+2.09%)
Taking everything into account, ZVRA scores 4 out of 10 in our fundamental rating. ZVRA was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ZVRA have multiple concerns. ZVRA is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year ZVRA was profitable.
ZVRA had a negative operating cash flow in the past year.
ZVRA had negative earnings in each of the past 5 years.
In the past 5 years ZVRA reported 4 times negative operating cash flow.
1.2 Ratios
ZVRA's Return On Assets of 13.08% is amongst the best of the industry. ZVRA outperforms 94.27% of its industry peers.
ZVRA has a better Return On Equity (26.53%) than 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.08% | ||
| ROE | 26.53% | ||
| ROIC | N/A |
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ZVRA (41.86%) is better than 97.92% of its industry peers.
ZVRA has a Gross Margin of 93.88%. This is amongst the best in the industry. ZVRA outperforms 95.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 41.86% | ||
| GM | 93.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZVRA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ZVRA has been increased compared to 5 years ago.
ZVRA has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.82, we must say that ZVRA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ZVRA (0.82) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.46 indicates that ZVRA is not too dependend on debt financing.
ZVRA has a worse Debt to Equity ratio (0.46) than 61.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.82 |
ROIC/WACCN/A
WACC9.04%
2.3 Liquidity
A Current Ratio of 8.62 indicates that ZVRA has no problem at all paying its short term obligations.
ZVRA has a Current ratio of 8.62. This is in the better half of the industry: ZVRA outperforms 77.60% of its industry peers.
A Quick Ratio of 8.57 indicates that ZVRA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.57, ZVRA is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.57 |
3. Growth
3.1 Past
ZVRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 122.84%, which is quite impressive.
Looking at the last year, ZVRA shows a very strong growth in Revenue. The Revenue has grown by 240.47%.
Measured over the past years, ZVRA shows a quite strong growth in Revenue. The Revenue has been growing by 12.96% on average per year.
EPS 1Y (TTM)122.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.55%
Revenue 1Y (TTM)240.47%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%605.36%
3.2 Future
Based on estimates for the next years, ZVRA will show a very strong growth in Earnings Per Share. The EPS will grow by 30.19% on average per year.
Based on estimates for the next years, ZVRA will show a very strong growth in Revenue. The Revenue will grow by 80.69% on average per year.
EPS Next Y154.27%
EPS Next 2Y49.92%
EPS Next 3Y41.65%
EPS Next 5Y30.19%
Revenue Next Year392.47%
Revenue Next 2Y175.62%
Revenue Next 3Y130.52%
Revenue Next 5Y80.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.11, the valuation of ZVRA can be described as rather expensive.
Based on the Price/Earnings ratio, ZVRA is valued cheaply inside the industry as 80.73% of the companies are valued more expensively.
ZVRA's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.45.
ZVRA is valuated correctly with a Price/Forward Earnings ratio of 15.36.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ZVRA indicates a rather cheap valuation: ZVRA is cheaper than 81.25% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, ZVRA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.11 | ||
| Fwd PE | 15.36 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ZVRA's earnings are expected to grow with 41.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y49.92%
EPS Next 3Y41.65%
5. Dividend
5.1 Amount
ZVRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.6
-0.45 (-4.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners63.87%
Inst Owner ChangeN/A
Ins Owners0.73%
Ins Owner Change20.36%
Market Cap482.80M
Revenue(TTM)84.39M
Net Income(TTM)35.33M
Analysts84.29
Price Target24.48 (184.65%)
Short Float %12.92%
Short Ratio3.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.59%
Min EPS beat(2)-20.8%
Max EPS beat(2)71.99%
EPS beat(4)2
Avg EPS beat(4)13.08%
Min EPS beat(4)-67.34%
Max EPS beat(4)71.99%
EPS beat(8)3
Avg EPS beat(8)-5.61%
EPS beat(12)4
Avg EPS beat(12)-9.16%
EPS beat(16)5
Avg EPS beat(16)-12.64%
Revenue beat(2)1
Avg Revenue beat(2)4.28%
Min Revenue beat(2)-4.04%
Max Revenue beat(2)12.59%
Revenue beat(4)3
Avg Revenue beat(4)14.7%
Min Revenue beat(4)-4.04%
Max Revenue beat(4)32.28%
Revenue beat(8)5
Avg Revenue beat(8)4.12%
Revenue beat(12)7
Avg Revenue beat(12)14.01%
Revenue beat(16)9
Avg Revenue beat(16)10.43%
PT rev (1m)0%
PT rev (3m)0.6%
EPS NQ rev (1m)131.58%
EPS NQ rev (3m)114.54%
EPS NY rev (1m)0%
EPS NY rev (3m)28.4%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)7.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.11 | ||
| Fwd PE | 15.36 | ||
| P/S | 5.72 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.63 | ||
| P/tB | 3.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.45
EY5.23%
EPS(NY)0.56
Fwd EY6.51%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS1.5
BVpS2.37
TBVpS2.17
PEG (NY)0.12
PEG (5Y)N/A
Graham Number4.9
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.08% | ||
| ROE | 26.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 41.86% | ||
| GM | 93.88% | ||
| FCFM | N/A |
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 128.58% | ||
| Cap/Sales | 8.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.57 | ||
| Altman-Z | 0.82 |
F-Score6
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)44.3%
Cap/Depr(5y)36.5%
Cap/Sales(3y)9.12%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)122.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.55%
EPS Next Y154.27%
EPS Next 2Y49.92%
EPS Next 3Y41.65%
EPS Next 5Y30.19%
Revenue 1Y (TTM)240.47%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%605.36%
Revenue Next Year392.47%
Revenue Next 2Y175.62%
Revenue Next 3Y130.52%
Revenue Next 5Y80.69%
EBIT growth 1Y66.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.53%
EBIT Next 3Y44.58%
EBIT Next 5Y33.33%
FCF growth 1Y-36.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.98%
OCF growth 3YN/A
OCF growth 5YN/A
ZEVRA THERAPEUTICS INC / ZVRA FAQ
What is the fundamental rating for ZVRA stock?
ChartMill assigns a fundamental rating of 4 / 10 to ZVRA.
What is the valuation status of ZEVRA THERAPEUTICS INC (ZVRA) stock?
ChartMill assigns a valuation rating of 5 / 10 to ZEVRA THERAPEUTICS INC (ZVRA). This can be considered as Fairly Valued.
What is the profitability of ZVRA stock?
ZEVRA THERAPEUTICS INC (ZVRA) has a profitability rating of 3 / 10.
Can you provide the financial health for ZVRA stock?
The financial health rating of ZEVRA THERAPEUTICS INC (ZVRA) is 3 / 10.
What is the expected EPS growth for ZEVRA THERAPEUTICS INC (ZVRA) stock?
The Earnings per Share (EPS) of ZEVRA THERAPEUTICS INC (ZVRA) is expected to grow by 154.27% in the next year.